Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
03:05pTime To Trust Gilead Again  
11:01aKBC Group NV Cuts Stake in Gilead Sciences, Inc. $GILD  
08:41aGilead Sciences $GILD Receiving Somewhat Favorable Press Coverage, Report Sho.. 
04:12aGilead Sciences, Inc. $GILD Given a $96.00 Price Target by Berenberg Bank Ana.. 
01:46aGilead Sciences, Inc. $GILD Given Hold Rating at Maxim Group  
10/20$GILD held its 10-week (and 50-day) well this week. Continues to look like co..
2
10/20Gilead Sciences's hold rating reiterated at BMO Capital Markets. $82.00 PT.  
10/20BMO Capital Keeps a Hold Rating on Gilead Sciences $GILD  
10/20  
10/20"Like Novartis’s therapy, which was priced at $475k, Gilead’s treatment comma..
4
10/2050 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
10/20#gold #price GoldMarketNews.EU Celgene Could Be the Best CAR-T Stock to Buy, .. 
10/20Why This Pharma May be the Best CAR-T Bet, Not Gilead
1
10/20  
10/20  
10/20Gilead Sciences, Inc. $GILD Expected to Announce Quarterly Sales of $6.31 Bil.. 
10/20SWING TRADE ALERT: Recent $GILD technical alerts: Doji - Bearish? plus 12 mor.. 
10/20Promotion at Gilead; trio of R&D excecs leave Moderna; and Bayer poaches .. 
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20Gilead Slaps Mega-Price on Its Newly Approved CAR-T: Motley Fool  
10/20BRIEF-Gilead announces multiple scientific presentations  
10/20  
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20$GILD Gilead Announces Multiple Scientific Presentations Demonstrating High C.. 
10/20Brainstorm Health: Thrive Global Samsung App, Gilead Cancer Gene Therapy, Lif..
1
10/20Gilead Sciences, Inc. $GILD Holdings Raised by GW Henssler & Associates L.. 
10/20Gilead Sciences, Inc. $GILD Holdings Raised by GW Henssler & Associates L.. 
10/20Gilead Sciences, Inc. $GILD Stake Raised by Cornerstone Capital Inc.  
10/20FDA approves Gilead cancer gene therapy; price set at $373,000
26
10/19[email protected] goes after $GILD on $373K price of Yescarta. Calls on Trump &..
5
10/19  
10/19  
10/19We discuss $GILD CAR-T approval, up next on @PowerLunch
1
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
2
10/1935 Stocks Moving In Thursday's Mid-Day Session
3
10/1950 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
10/19Gilead Kite's treatment becomes first FDA approved CAR-T therapy #KitePharma,.. 
10/19Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug  
10/19Gilead receives FDA approval for Kite's breakthrough CAR-T therapy for .. 
10/19Gilead shares climb after its L.A.-area Kite unit gets FDA approval for lymph.. 
10/19LIVE: Gilead gains 4% after FDA approves lymphoma drug $GILD -
4
10/19Gilead: A New Cancer Drug! Great…But You Still Overpaid for Kite  
10/19Gilead cell-therapy drug Yescarta gets FDA approval
1
10/19ICYMI following Wed's mkt close: Another CAR-T rides into town as FDA approva.. 
10/19Gilead gets FDA go-ahead for second CAR-T . Read more about the $12 bln deal ..
6
10/19WATCH: Stocks we're watching today - $VZ, $AXP, $NKE, $APRN, $GILD
4
10/19Gilead Sciences Yescarta Drug Approved By FDA  
10/19A Kite-Gilead #cancer treatment that's part of 'a big new field of medicine' .. 
10/19Gilead: A New Cancer Drug! Great?But You Still Overpaid for Kite  
More tweets
Qtime:506
Financials ($)
Sales 2017 25 966 M
EBIT 2017 15 929 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 85,3 $
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985